Pediatric Cancer Drug Supply Act of 2024

HR 6963, the Pediatric Cancer Drug Supply Act of 2024, creates a federal pilot program to prevent shortages of essential pediatric cancer drugs. The Secretary of Health and Human Services will enter agreements with manufacturers to maintain a 6-month reserve supply of each covered drug - defined as drugs on a list developed by the Secretary that treat pediatric cancer and meet specific criteria - held in the U.S. by manufacturers. Manufacturers must store extra inventory beyond normal levels, ensure drugs have over a year of shelf life, and allow the government to audit compliance. During shortages, the Secretary can order these reserves distributed to patients, with recipients paying the government's purchase price to replenish the supply. The program is funded with $500 million for fiscal year 2024.